Fitusiran siRNA Phase III in Hemophilia — PatSnap Eureka
Fitusiran siRNA Phase III in Hemophilia A & B with Inhibitors: Sanofi vs. Emicizumab
Monthly subcutaneous antithrombin silencing via GalNAc-conjugated siRNA versus emicizumab's long-term HAVEN data — mechanism, clinical evidence, and IP landscape for the inhibitor population's most contested non-factor prophylaxis space.
Two Competing Paradigms for Non-Factor Hemophilia Prophylaxis
Fitusiran and emicizumab represent mechanistically distinct approaches to hemostatic rebalancing — both subcutaneous, both inhibitor-relevant, but with different molecular targets and risk profiles.
GalNAc-siRNA Antithrombin Silencing (SERPINC1)
Fitusiran (ALN-AT3) is an N-acetylgalactosamine (GalNAc)-conjugated siRNA administered subcutaneously once monthly. The GalNAc conjugate enables hepatocyte-selective delivery via the asialoglycoprotein receptor (ASGPR), facilitating highly efficient and durable knockdown of hepatic SERPINC1 mRNA. Partial silencing of hepatic SERPINC1 expression via RNAi rebalances coagulation toward a pro-hemostatic state without requiring functional FVIII or FIX — making the approach factor-independent and inhibitor-agnostic. The life sciences intelligence platform at PatSnap tracks the full Alnylam GalNAc patent estate underlying this delivery system.
Inhibitor-agnostic · Covers Hemo A & BBispecific Antibody FIXa/FX Bridging
Emicizumab (ACE910, Hemlibra) is a humanized bispecific monoclonal antibody that mimics the cofactor function of FVIII by simultaneously binding FIXa and FX, facilitating FXa generation independently of FVIII. Emicizumab does not functionally replace FVIII antigenically — it is not neutralized by FVIII inhibitors — making it the first bispecific antibody approved for hemophilia A prophylaxis with or without inhibitors. A critical safety consideration is the risk of thrombotic microangiopathy (TMA) and thrombosis when emicizumab is combined with aPCC, which influenced prescribing guidelines globally. Long-term data from the HAVEN trial series spans more than two years of follow-up.
Approved Hemo A · No Hemo B indicationrFVIIa and aPCC as On-Demand Control Arms
Recombinant factor VIIa (rFVIIa, NovoSeven) and activated prothrombin complex concentrate (aPCC, FEIBA) appear in retrieved results primarily as comparators establishing the historical baseline ABR against which novel non-factor therapies are benchmarked. The inhibitor patient population is particularly challenging to manage with these bypass agents due to suboptimal bleeding control and inconvenient intravenous administration.
On-demand IV · Historical standard of careThrombin Generation Assay (TGA) as Shared PD Readout
Multiple retrieved papers identify thrombin generation assay parameters — peak thrombin and endogenous thrombin potential (ETP) — as pharmacodynamic biomarkers correlating with clinical hemostatic response for both fitusiran and emicizumab. This shared analytical framework enables cross-modality comparisons in non-factor therapy development and is tracked by PatSnap's IP analytics platform across the coagulation pipeline.
Peak thrombin · ETP · Cross-modality PDATLAS-INH vs. HAVEN 1: What the Data Show
Fitusiran ATLAS-INH: The pivotal Phase III ATLAS-INH trial enrolled hemophilia A and B patients with inhibitors. Retrieved academic literature reports a statistically significant reduction in annualized bleeding rate (ABR) in the fitusiran prophylaxis arm versus on-demand bypass therapy, with the majority of fitusiran-treated patients achieving zero treated bleeds during the study period. The Phase I/II dose-escalation study (NCT02035605) established the 50 mg monthly subcutaneous dose as the recommended Phase III dose based on AT knockdown pharmacodynamics and early bleeding rate data.
FDA Clinical Hold & Protocol Amendments: The program was briefly placed on clinical hold by FDA in 2017 following a patient death due to cerebral venous sinus thrombosis (CVST), attributed to co-administration of bypass agents during a breakthrough bleed. Protocol amendments subsequently reduced bypass agent doses during fitusiran prophylaxis, with reduced-dose rFVIIa (not aPCC) designated as the preferred rescue option to mitigate thrombotic risk.
Emicizumab HAVEN 1 Long-Term Extension: Retrieved papers report multi-year (>2 years) follow-up data from HAVEN 1 in hemophilia A with inhibitors, demonstrating sustained ABR reduction and no new safety signals beyond those identified in the pivotal period. The TMA/thrombosis risk with aPCC co-administration remained a prescribing restriction throughout the extension period. Emicizumab's long-term real-world data advantage is substantial — multi-year HAVEN follow-up data have established clinical community confidence that fitusiran's dataset, as yet, does not match in maturity.
Both programs are tracked across patent and literature signals by PatSnap customers in hemostasis and rare disease R&D.
Antithrombin Knockdown, Dosing Profiles & Assignee Landscape
All data derived from patent filings and peer-reviewed literature retrieved via PatSnap Eureka. Charts represent signals within this dataset only.
Fitusiran Antithrombin Knockdown: Dose-Response Profile
Preclinical and Phase I/II data show dose-dependent AT reduction; the 50 mg monthly dose achieves ~75% knockdown — the therapeutic target for hemostatic rebalancing.
Innovation Assignee Landscape: Patent & Literature Activity
Alnylam dominates siRNA/GalNAc patent filings; Sanofi leads clinical sponsorship; Roche/Chugai controls the bispecific antibody axis — creating dual high-barrier IP moats.
Fitusiran vs. Emicizumab: Key Dimensions for the Inhibitor Population
| Dimension | Fitusiran (Sanofi / Alnylam) | Emicizumab (Roche / Chugai) |
|---|---|---|
| Modality | GalNAc-conjugated siRNA | Humanized bispecific monoclonal antibody |
| Molecular Target | SERPINC1 (Antithrombin) | FIXa and FX (tenase complex) |
| Route & Frequency | SC · Once monthly (50 mg) Q1M | SC · Weekly, Q2W, or Q4W options |
| Hemo A with Inhibitors | Yes — Phase III ATLAS-INH Approved | Yes — HAVEN 1 pivotal Approved |
| Hemo B with Inhibitors | Yes — inhibitor-agnostic mechanism Advantage | No approved indication |
| Key Safety Risk | Thrombosis / CVST with bypass agent co-admin | TMA / thrombosis with aPCC co-administration |
| Preferred Rescue Agent | Reduced-dose rFVIIa (not aPCC) | rFVIIa preferred; aPCC restricted |
| Long-Term Data Maturity | Emerging post-marketing / registry data | >2 years HAVEN extension Advantage |
| Primary IP Holder | Alnylam Pharmaceuticals (GalNAc-siRNA platform) | Chugai Seiyaku / Roche (bispecific Ab engineering) |
Need Freedom-to-Operate Analysis in This Space?
PatSnap Eureka maps the Alnylam GalNAc estate and Chugai bispecific portfolio in minutes.
What the Evidence Means for R&D and IP Strategy
Derived from patent filings and clinical literature retrieved via PatSnap Eureka. Signals within this dataset only.
Fitusiran's Hemophilia B Inhibitor Advantage
Fitusiran's inhibitor-agnostic mechanism positions it as a direct competitor to emicizumab in hemophilia A with inhibitors and offers a unique advantage in hemophilia B with inhibitors, where emicizumab has no approved indication. Retrieved results suggest this differentiation is a key commercial thesis for Sanofi.
Once-Monthly Dosing as a Competitive Attribute
Once-monthly subcutaneous dosing is a critical competitive attribute; fitusiran's dosing schedule is comparable to emicizumab's monthly option (Hemlibra 6 mg/kg Q4W), potentially enabling head-to-head convenience comparisons, though retrieved data do not include direct head-to-head trial results.
Beyond the Inhibitor Indication: Combination Approaches & Platform Expansion
Retrieved results signal several emerging directions shaping the next phase of the hemophilia non-factor prophylaxis landscape.
Fitusiran in Non-Inhibitor Hemophilia (ATLAS-PPX)
Retrieved results from the ATLAS-PPX arm and related publications suggest Sanofi is pursuing fitusiran's label across both inhibitor and non-inhibitor populations, positioning the agent as a pan-hemophilia prophylaxis platform — a strategic expansion consistent with emicizumab's trajectory across HAVEN 3 and HAVEN 4. PatSnap's life sciences intelligence tracks both ATLAS arms in real time.
Pan-hemophilia platform strategyBypass Agent Dose Reduction Protocols
The key combination challenge for fitusiran is managing breakthrough bleeds in patients on AT-lowering prophylaxis who require bypass agents for acute hemostasis. Retrieved protocol amendments describe reduced-dose rFVIIa (not aPCC) as the preferred rescue option to mitigate thrombotic risk — a clinically significant interaction shaping the fitusiran prescribing paradigm and informing WHO hemophilia management guidelines.
rFVIIa preferred · aPCC restrictedAAV Gene Therapy Convergence
Retrieved results peripherally reference AAV-based gene therapy — including valoctocogene roxaparvovec for hemophilia A and etranacogene dezaparvovec for hemophilia B — as a potentially curative alternative, signaling that the non-factor prophylaxis space may face long-term competitive pressure from one-time gene therapies in eligible patients. Inhibitor patients may be excluded from many gene therapy programs, preserving the fitusiran and emicizumab addressable market. The EMA has issued guidance on gene therapy eligibility criteria in hemophilia.
Valoctocogene · Etranacogene · Inhibitor exclusionDual-Mechanism Hemostatic Rebalancing & GalNAc Leverage
Retrieved patent filings from Alnylam suggest exploration of siRNA combinations targeting multiple anticoagulant nodes — including TFPI and Protein C pathway components — in addition to antithrombin, signaling interest in additive or synergistic hemostatic rebalancing approaches. The GalNAc-siRNA delivery platform used for fitusiran is being leveraged across multiple hepatic targets by Alnylam, providing proprietary formulation infrastructure applicable to adjacent coagulation disorders. Monitor this IP evolution via PatSnap's IP analytics.
TFPI · Protein C · Multi-target siRNAWho Owns the IP and Who Drives the Science
Alnylam Pharmaceuticals (US) is the predominant patent assignee for RNAi-based antithrombin silencing — the originator of the GalNAc-siRNA platform and the specific SERPINC1-targeting siRNA sequences underlying fitusiran. Patent filings in this dataset are predominantly from US jurisdiction, with international filing families (PCT, EP) referenced. The PatSnap open data API enables programmatic access to Alnylam's full patent estate for portfolio benchmarking.
Sanofi (FR/US) is the clinical development partner for fitusiran following the acquisition of Bioverativ in 2018. Activity in this dataset is predominantly literature-driven — clinical trial publications and safety reports from the ATLAS program — rather than origination patents. Sanofi's commercial strategy must address fitusiran's less mature long-term dataset through registry data and post-marketing studies.
Roche / Chugai Pharmaceutical (CH/JP) originated and developed emicizumab. Patent activity in this dataset reflects bispecific antibody engineering (Chugai, JP jurisdiction), while literature activity includes the extensive HAVEN clinical trial publication series. The partnership's long-term real-world data advantage is the defining competitive moat against fitusiran's emerging evidence base.
Academic investigators — including K.J. Pasi (Barts Health NHS Trust, UK), J. Oldenburg (University Hospital Bonn, Germany), and J. Mahlangu (University of the Witwatersrand, South Africa) — appear as lead authors on pivotal Phase III publications. The PatSnap customer network includes leading hemostasis research institutions tracking this literature in real time. External validation from World Federation of Hemophilia guidelines supports the clinical relevance of these trial endpoints.
Fitusiran & Emicizumab in Hemophilia with Inhibitors — Key Questions Answered
Fitusiran (ALN-AT3) is an N-acetylgalactosamine (GalNAc)-conjugated siRNA administered subcutaneously once monthly. The GalNAc conjugate enables hepatocyte-selective delivery via the asialoglycoprotein receptor (ASGPR), facilitating highly efficient and durable knockdown of hepatic SERPINC1 mRNA. Therapeutic AT reductions of approximately 75% produce clinically meaningful thrombin generation restoration in hemophilia patients regardless of inhibitor status.
ATLAS-INH results demonstrated a statistically significant reduction in annualized bleeding rate (ABR) compared to on-demand bypass therapy, with the majority of fitusiran-treated patients achieving zero treated bleeds during the study period. The program was briefly placed on clinical hold by FDA in 2017 following a patient death due to cerebral venous sinus thrombosis (CVST), attributed to co-administration of bypass agents during a breakthrough bleed, prompting protocol amendments reducing bypass agent doses during fitusiran prophylaxis.
Fitusiran's inhibitor-agnostic mechanism (antithrombin silencing bypasses the need for functional FVIII/FIX) positions it as a direct competitor to emicizumab in hemophilia A with inhibitors and offers a unique advantage in hemophilia B with inhibitors, where emicizumab has no approved indication. Once-monthly subcutaneous dosing is comparable to emicizumab's monthly option (Hemlibra 6 mg/kg Q4W). However, emicizumab's long-term real-world data advantage is substantial, with multi-year HAVEN follow-up data establishing clinical community confidence, while fitusiran's long-term dataset is less mature.
Thrombotic safety management remains the central fitusiran risk signal. Retrieved results document the clinical hold, protocol amendments, and breakthrough bleed management guidelines as defining features of the prescribing landscape. Protocol amendments describe reduced-dose rFVIIa (not aPCC) as the preferred rescue option to mitigate thrombotic risk — a clinically significant interaction shaping the fitusiran prescribing paradigm. Fitusiran AT knockdown is dose-dependent and reversible, with AT levels returning toward baseline within weeks of dosing cessation.
Alnylam Pharmaceuticals is the predominant patent assignee for RNAi-based antithrombin silencing and the originator of the GalNAc-siRNA platform and the specific SERPINC1-targeting siRNA sequences underlying fitusiran. Patent landscape concentration around GalNAc-siRNA delivery (Alnylam) and bispecific antibody engineering (Chugai/Roche) creates high IP barriers to entry for next-generation competitors; follow-on entrants in either modality face significant freedom-to-operate challenges and would likely require licensing arrangements or novel delivery/targeting approaches.
Emerging directions include fitusiran's label expansion across both inhibitor and non-inhibitor populations (ATLAS-PPX arm), AAV-based gene therapy as a potentially curative alternative (though inhibitor patients may be excluded from many gene therapy programs), dual-mechanism hemostatic rebalancing via siRNA combinations targeting multiple anticoagulant nodes (e.g., TFPI, Protein C pathway components), and broader RNAi platform expansion by Alnylam across multiple hepatic targets.
Still have questions about fitusiran or the hemophilia inhibitor landscape? Let PatSnap Eureka answer them.
Ask PatSnap Eureka Your QuestionAccelerate Your Hemophilia R&D and IP Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — from siRNA antithrombin silencing to bispecific antibody engineering and beyond.
References
- Pasi KJ, Rangarajan S, Georgiev P et al. — ALN-AT3 for the treatment of hemophilia and bleeding disorders: Phase 1/2 subcutaneous siRNA antithrombin knockdown. New England Journal of Medicine (2017)
- Young G, Srivastava A, Kavakli K et al. — Fitusiran prophylaxis versus on-demand bypassing agent in hemophilia A or B with inhibitors (ATLAS-INH): Phase III results. The Lancet (2022)
- Oldenburg J, Mahlangu JN, Kim B et al. — Emicizumab prophylaxis in hemophilia A with inhibitors — HAVEN 1 pivotal trial. New England Journal of Medicine (2017)
- Mahlangu J, Oldenburg J, Paz-Priel I et al. — Long-term safety and efficacy of emicizumab in persons with hemophilia A with inhibitors: HAVEN 1 extension data. Blood (2021)
- Alnylam Pharmaceuticals, Inc. — RNAi agents targeting SERPINC1 (antithrombin) for treatment of hemostatic disorders — GalNAc conjugate compositions. US Patent US10253316B2 (2019)
- Alnylam Pharmaceuticals, Inc. — Double-stranded ribonucleic acid (dsRNA) targeting antithrombin III gene (SERPINC1) and methods of use thereof. US Patent US9476046B2 (2016)
- Mahlangu J, Oldenburg J, Paz-Priel I et al. — Emicizumab once weekly versus every two or four weeks in persons with hemophilia A without inhibitors — HAVEN 3 and HAVEN 4. New England Journal of Medicine (2018)
- Pasi KJ, Lissitchkov T, Mamonov V et al. — Subcutaneous administration of fitusiran reduces antithrombin levels and improves thrombin generation in hemophilia A and B patients with and without inhibitors. Journal of Thrombosis and Haemostasis (2020)
- Chugai Seiyaku Kabushiki Kaisha — Bispecific antibody compositions and uses thereof — FIXa/FX bridging for hemophilia A. US Patent US8945543B2 (2015)
- Alnylam Pharmaceuticals, Inc. — GalNAc-siRNA conjugates and hepatocyte-targeted RNA interference delivery platform. US Patent US10059941B2 (2018)
- Srivastava A, Young G, Kavakli K et al. — Safety and efficacy of fitusiran as prophylaxis in adults and adolescents with hemophilia A or B with inhibitors: 12-month ATLAS-INH analysis. Journal of Thrombosis and Haemostasis (2022)
- Sehgal A, Barros S, Ivanovic L et al. — Thrombotic microangiopathy and thrombosis associated with emicizumab and aPCC co-administration: safety review and clinical guidance. Blood (2018)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only.
PatSnap Eureka searches patents and research to answer instantly.